11 ottobre 2021

Dompé expand Commercial Operations for Oxervate to Canada

Dompé farmaceutici S.p.A and Dompé U.S. Inc. (collectively Dompé), announce that they are planning to expand Commercial Operations for Oxervate (cenegermin ophthalmic solution) to Canada.

Dompé farmaceutici S.p.A and Dompé U.S. Inc. (collectively Dompé), announce that they are planning to expand Commercial Operations for Oxervate (cenegermin ophthalmic solution) to Canada. Preparations to enter the market started earlier in 2021 and recently the Human Drug Advisory Panel (HDAP) of PMPRB recommended the classification of Oxervate as providing a Breakthrough Level of Therapeutic Improvement for the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults. In their review comments, HDAP, the scientific review board of the Canadian Patented Medicine Pricing Review Board (PMPRB) acknowledged the potential of an externally applied agent to induce corneal epithelial healing and alter the natural progression of the disease which may otherwise lead to profound loss of vision’ as clinically relevant and affirmed that there are no therapeutic comparators for Oxervate currently available in Canada. “We are proud to be delivering this important treatment to more people in living with neurotrophic keratitis,” said Ashley Kline, Head of Global Biotech and General Manager for Dompé U.S. “At Dompé, our priority is ensuring that NK patients can access the clinical benefits of Oxervate. We are committed to continuously invest in innovation in the areas of unmet medical need.”

Dompé farmaceutici S.p.A. Socio Unico / Capitale sociale € 50.000.000,00
REA MI 289519 - Registro Imprese di Milano / Codice Fiscale e Partita IVA (VAT) IT00791570153

Chiudi